1027035-76-2

Upstream product

• 1204703-62-7 methyl 4-(azidomethyl)-2-methoxybenzoate 
• 57757-74-1 3-Methoxy-4-(methoxycarbonyl)benzyl Alcohol 
• 189094-76-6 methyl 4-[(acetyloxy)methyl]-2-methoxybenzoate 
• 74733-27-0 methyl 4-bromomethyl-2-methoxybenzoate 
• 81245-24-1 methyl 4-methyl-2-methoxybenzoate 
• 4670-56-8 methyl 2-hydroxy-4-methylbenzoate 
• 50-85-1 2-hydroxy-p-toluic acid 
• 406719-76-4 methyl 4-cyano-2-methoxybenzoate 
• 89469-52-3 2-methoxy-4-cyano-benzoic acid 

Downstream Products

• 1289571-14-7 4-{[(imidazole-1-carbonyl)-amino]-methyl}-2-methoxy-benzoic acid methyl ester 
• 1289570-73-5 rac-4-(((2S,3S,4S)-2-(3-chloro-2-fluorophenyl)-3-(4-chloro-2-fluorophenyl)-3-cyano-4-neopentylpyrrolidine-1-carboxamido)methyl)-2-methoxybenzoic acid 
• 1289570-74-6 4-(((2R,3R,4R)-2-(3-chloro-2-fluorophenyl)-3-(4-chloro-2-fluorophenyl)-3-cyano-4-neopentylpyrrolidine-1-carboxamido)methyl)-2-methoxybenzoic acid 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOUNDS

This invention relates to compounds that inhibit or modulate the activity of Chk-1 kinase. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.

NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS

There are provided compounds of the formula wherein X, Y, R1, R2, R3, R3, R4, and R5 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof which are useful as anticancer agents.